Transient mtor inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Yang, Zhaojuan ^a   Zhang, Li ^a   Ma, Aihui ^a   Liu, Lanlan ^a,b   Li, Jinjun ^a   Gu, Jianren ^a   Liu, Yongzhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RAPAMYCIN; RHEB PROTEIN; S6 KINASE; SHORT HAIRPIN RNA; ANTINEOPLASTIC ANTIBIOTIC; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MTOR PROTEIN, MOUSE; PEPTIDE; PROTEIN P53; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL RENEWAL; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CARCINOGENICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER TUMOR; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LIVER; LIVER CELL CARCINOMA; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOPROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; NEOPLASTIC STEM CELLS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82455174375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028405     Document Type: Article

References (62)

1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
2. Liu S, Wicha MS, (2010) Targeting breast cancer stem cells. J Clin Oncol 28: 4006-4012.
3. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
4. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
5. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
6. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9: 50-63.
7. Kemper K, Grandela C, Medema JP, (2010) Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1: 387-395.
8. Curtin JC, Lorenzi MV, (2010) Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1: 563-577.
9. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, et al. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19: 86-100.
10. Korkaya H, Paulson A, Iovino F, Wicha MS, (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
11. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106: 268-273.
12. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, et al. (2010) TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 18: 655-668.
13. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, et al. (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463: 676-680.
14. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
15. Kenerson HL, Aicher LD, True LD, Yeung RS, (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62: 5645-5650.
16. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
17. Sansal I, Sellers WR, (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
18. Inoki K, Corradetti MN, Guan KL, (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
19. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
20. Vignot S, Faivre S, Aguirre D, Raymond E, (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537.
21. Easton JB, Houghton PJ, (2006) mTOR and cancer therapy. Oncogene 25: 6436-6446.
22. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, et al. (2008) Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22: 2172-2177.
23. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, et al. (2010) Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 70: 3287-3298.
24. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, et al. (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7: 1758-1764.
25. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, et al. (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25: 7029-7040.
26. Shaw RJ, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
27. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, et al. (2010) Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10: 368.
28. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, et al. (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27: 193-198.
29. Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS, (2009) mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5: 279-289.
30. Easley CAt, Ben-Yehudah A, Redinger CJ, Oliver SL, Varum ST, et al. (2010) mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cell Reprogram 12: 263-273.
31. Campbell TB, Basu S, Hangoc G, Tao W, Broxmeyer HE, (2009) Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation. Blood 114: 3392-3401.
32. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, et al. (2008) TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 205: 2397-2408.
33. Schewe DM, Aguirre-Ghiso JA, (2008) ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci U S A 105: 10519-10524.
34. Sunayama J, Matsuda KI, Sato A, Tachibana K, Suzuki K, et al. (2010) Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells. Stem Cells 28: 1930-1939.
35. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104: 16158-16163.
36. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, et al. (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164.
37. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
38. Song W, Li H, Tao K, Li R, Song Z, et al. (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218.
39. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, et al. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466.
40. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
41. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
42. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
43. Sabatini DM, (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
44. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
45. Horst D, Kriegl L, Engel J, Kirchner T, Jung A, (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289.
46. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, et al. (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218.
47. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
48. You H, Ding W, Rountree CB, (2010) Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51: 1635-1644.
49. Ding W, Mouzaki M, You H, Laird JC, Mato J, et al. (2009) CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49: 1277-1286.
50. Rountree CB, Barsky L, Ge S, Zhu J, Senadheera S, et al. (2007) A CD133-expressing murine liver oval cell population with bilineage potential. Stem Cells 25: 2419-2429.
51. Rountree CB, Senadheera S, Mato JM, Crooks GM, Lu SC, (2008) Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 47: 1288-1297.
52. Rountree CB, Ding W, He L, Stiles B, (2009) Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 27: 290-299.
53. Tee AR, Blenis J, Proud CG, (2005) Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett 579: 4763-4768.
54. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, et al. (2009) Rapamycin decelerates cellular senescence. Cell Cycle 8: 1888-1895.
55. Demidenko ZN, Shtutman M, Blagosklonny MV, (2009) Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 8: 1896-1900.
56. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, et al. (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2: 344-352.
57. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, et al. (2007) Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258: 286-290.
58. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, et al. (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7: 489-497.
59. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014.
60. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959.
61. Zender L, Xue W, Cordon-Cardo C, Hannon GJ, Lucito R, et al. (2005) Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 70: 251-261.
62. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267.